

Edgar Filing: CARACO PHARMACEUTICAL LABORATORIES LTD - Form 8-K

CARACO PHARMACEUTICAL LABORATORIES LTD

Form 8-K

October 20, 2004

=====

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

October 20, 2004
(Date of report)

CARACO PHARMACEUTICAL LABORATORIES, LTD.

(Exact name of registrant as specified in its charter)

Michigan

0-24676

38-2505723

(State or other jurisdiction of
incorporation)

(Commission file number)

(I.R.S. employer
identification no)

1150 Elijah McCoy Drive, Detroit, Michigan 48202

(Address of principal executive offices)

(313) 871-8400

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 140.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the

Edgar Filing: CARACO PHARMACEUTICAL LABORATORIES LTD - Form 8-K

Exchange Act (17 CFR 240.13e-4(c))

=====

ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION AND ITEM 7.01.
REGULATION FD DISCLOSURE

On October 20, 2004, registrant announced its results of operations for the quarter ended September 30, 2004, as set forth in the press release included as Exhibit 99.1 hereto, which is incorporated herein by reference.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

c) Exhibits.

Exhibit No.	Description
99.1	Press Release of Caraco Pharmaceutical Laboratories, Ltd., dated October 20, 2004 announcing third quarter of 2004 results of operations

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CARACO PHARMACEUTICAL LABORATORIES, LTD.

Date: October 20, 2004

By: /s/ Jitendra N. Doshi

Jitendra N. Doshi
Chief Executive Officer

3

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release of Caraco Pharmaceutical Laboratories, Ltd., dated October 20, 2004 announcing third quarter of 2004 results of operations.

4